A novel and efficient iron-catalyzed cycloaddition reaction using readily available 2,3-diaryl-2H-azirines and primary amides is reported. A wide range of trisubstituted oxazoles could be achieved in good yields with good functional group compatibility. In this transformation, two C–N bonds were cleaed and new C–N and C–O bonds were formed.
Synthesis of Extended Oxazoles III: Reactions of 2-(Phenylsulfonyl)methyl-4,5-diaryloxazoles
作者:Pravin C. Patil、Frederick A. Luzzio
DOI:10.1021/acs.joc.6b01280
日期:2016.11.4
2-((Phenylsulfonyl)methyl)-4,5-diphenyloxazole is a useful scaffold for synthetic elaboration at the 2-methylene position thereby affording extended oxazoles. The corresponding α-sulfonyl anion reacts smoothly with diverse alkyl halides giving monoalkylated (47–90%), dialkylated (50–97%), and cyclic (59–93%) products. The reductive desulfonylation of the monoalkylated and selected dialkylated products
An efficient synthesis of trisubstituted oxazoles via chemoselective O-acylations and intramolecular Wittig reactions
作者:Yi-Ling Tsai、Yu-Shiou Fan、Chia-Jui Lee、Chan-Hui Huang、Utpal Das、Wenwei Lin
DOI:10.1039/c3cc45883k
日期:——
Preparation of new types of trisubstituted oxazoles is realized via chemoselective O-acylations and intramolecular Wittig reactions with ester functionalities using in situ formed phosphorus ylides as key intermediates. A plausible reaction mechanism for this undiscovered chemistry is also proposed based on the existence of expected and rearranged isomeric oxazoles.
MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC
申请人:ANDERSSON Johan
公开号:US20090170934A1
公开(公告)日:2009-07-02
The present invention relates to a new process for the preparation of NO-donating compounds using a sulfonated intermediate. The invention relates to new intermediates prepared therein suitable for large scale manufacturing of NO-donating compounds. The invention further relates to the use of the new intermediates for the manufacturing of pharmaceutically active NO-donating compounds. The invention further relates to a substantially crystalline form of NO-donating NSAIDs, especially 2-[2-(nitrooxy)ethoxy]ethyl 2-[(2,6-dichlorophenyl)amino]phenyl}acetate, the preparation thereof and to pharmaceutical formulations containing said crystalline form and to the use of said crystalline form in the preparation of a medicament.